Clinical trials: Radiotherapy, active
Faecal Incontinence With Faecal Urgency, Rectal Cancer
Efficacy of a Novel High Intensive Percutaneous Tibial Nerve Stimulation on Faecal Incontinence in Patients With Low Anterior Resection Cancer Syndrome After Rectal Cancer Surgery
This study aims to assess and evaluate the clinical efficacy of an intensified form of Percutaneous tibial nerve stimulation (PTNS) compared to standard conservative treatment for low anterior resection syndrome (LARS).
- Conditions
- Faecal Incontinence With Faecal Urgency, Rectal Cancer, Radiotherapy Side Effects, Low Anterior Resection Syndrome (LARS>20)
- Trial name
- HiPLARS (NCT07862673)
- Testing
- Percutaneous Tibial Nerve Stimulation
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Region Skane
Breast Cancer, Quality of Life
Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy: a Single Institution Experience
This is a homogeneous, single institution, observational, non-interventional, prospective study of 500 patients who will be treated according to the standard protocol of adjuvant hypofractionated radiotherapy after breast…
- Conditions
- Breast Cancer, Quality of Life, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Survivorship
- Trial name
- Ipomammella (NCT03077191)
- Testing
- Quality of life measurement
- Where
- Italy
- Volunteers
- 410 people
- Sponsor
- IRCCS San Raffaele
Gynecologic Cancer, Radiotherapy Side Effect
Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)
This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy…
- Conditions
- Gynecologic Cancer, Radiotherapy Side Effect, Radiotherapy; Complications, Survivorship
- Trial name
- GYN-ART (NCT06306170)
- Testing
- Image Guided Radiotherapy
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS San Raffaele
Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy
- Trial name
- HCC-PULSAR (NCT07884877)
- Testing
- PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Samsung Medical Center
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste.
- Conditions
- Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy
- Trial name
- OSEM (NCT07885033)
- Testing
- ORAL CARE PRODUCT KIT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNCANCER LLC
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
This single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemotherapy (HAIC, for up to 4 cycles) with iparomlimab/tuvonralimab plus…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
- Trial name
- NCT07062055
- Testing
- Anti-VEGF, Immunotherapy, Local Therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shandong Cancer Hospital and Institute
Stereotactic Body Radiotherapy, 68Ga-MAA
Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy
Stereotactic body radiotherapy (SBRT) has an increasing role in the treatment of both primary and secondary lung tumors. However, lung SBRT remains associated with significant radiation induced lung injury (RILI).
- Conditions
- Stereotactic Body Radiotherapy, 68Ga-MAA, Lung Cancer (Diagnosis)
- Trial name
- Pegasus 2 (NCT07289646)
- Testing
- Conventional anatomical planning radiotherapy, Functional Lung avoidance planning
- Where
- 2 sites in France
- Volunteers
- 418 people
- Sponsor
- University Hospital, Brest
Head and Neck Cancer, Pelvic Cancer
Health Oriented Protocol for Epidermal Radiodermatitis
Radiation therapy is a standard treatment for malignant tumors of the head and neck and pelvic regions, used alone or in combination with chemotherapy.
- Conditions
- Head and Neck Cancer, Pelvic Cancer, Radiation Skin Injury, Gynecologic Cancer
- Trial name
- HOPE (NCT07129525)
- Testing
- Radiation therapy
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Neoplasms, Radiotherapy
Hypofractionated LocoRegional Radiotherapy in Breast Cancer
The primary objective of this study is to determine if hypofractionated RT delivered over 1 week to the breast or chest wall and regional nodes (26Gy in 5 daily fractions) following BCS or mastectomy, is non-inferior to…
- Conditions
- Breast Neoplasms, Radiotherapy, Lymphedema
- Trial name
- RHEAL (NCT04228991)
- Testing
- Locoregional radiation treatment - Conventional fractionation, Locoregional radiation treatment - Hypofractionation
- Where
- 20 sites in Canada
- Volunteers
- 588 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC)
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at…
- Conditions
- OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
- Trial name
- NCT06841172
- Testing
- radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shandong Cancer Hospital and Institute
HER2-positive Advanced Breast Cancer, Brain Metastases
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined…
- Conditions
- HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT07100600
- Testing
- Trastuzumab Rezetecan, FSRT or WBRT
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Henan Cancer Hospital
Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV)
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV), Postoperative Nausea and Vomiting
- Trial name
- NCT07868861
- Testing
- NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Small-cell Lung Cancer, Brain Metastases
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the…
- Conditions
- Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
- Trial name
- SHARP (NCT06457906)
- Testing
- Experimental group (SRS/SRT/Hypo-RT), Controled group (HA-WBRT)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Oropharyngeal Neoplasms, Robotic Surgery and/or Radiotherapy
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
To test a new radiation treatment design based on where your cancer is located. Most participants with oropharyngeal cancer are treated with radiation to both sides of the neck.
- Conditions
- Oropharyngeal Neoplasms, Robotic Surgery and/or Radiotherapy, Lymphoscintigraphy
- Trial name
- NCT06167291
- Testing
- Arm 1- Ipsilateral
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status.
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
- Trial name
- NCT06342167
- Testing
- Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support
- Where
- 10 sites in China
- Volunteers
- 57 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rectal Cancer, Radiotherapy
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
This is a prospective, single-arm, biomarker-stratified, multicenter phase 2 clinical trial. All enrolled patients first receive short-course radiotherapy (SCRT), followed by measurement of serum β-hydroxybutyrate (β-HB) levels…
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy
- Trial name
- NCT07847229
- Testing
- Short-course radiotherapy, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Tao Zhang
Borderline Resectable Carcinoma, Unresectable Cancer
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality.
- Conditions
- Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitor
- Trial name
- ILDR-03 (NCT07339488)
- Testing
- Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 inhibitors, Chemotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Chuangzhen Chen
HCC - Hepatocellular Carcinoma, Durvalumab
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton Radiotherapy
- Trial name
- Proton-STRIDE (NCT06999694)
- Testing
- Proton radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
HCC - Hepatocellular Carcinoma, Tremelimumab
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
- Trial name
- Photon-STRIDE (NCT06999707)
- Testing
- Photon radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Cancer Patients Receiving Radiotherapy for Kidney Malignancies
Efficacy Evaluation of Modified Zhixiao Tongmai Ning in Preventing Radiation-Induced Kidney Injury
This prospective randomized controlled study evaluates the clinical efficacy of modified Zhixiao Tongmai Ning in preventing radiation-induced kidney injury in cancer patients.
- Trial name
- NCT07849088
- Testing
- Modified Zhixiao Tongmai Ning, Standard Radiotherapy Alone
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Peking University First Hospital